Cardiac amyloidosis (CA) is an infiltrative/restrictive cardiomyopathy, caused by
the deposition of misfolded amyloid fibrils in the form of immunoglobulin light-chain
or transthyretin amyloid within the myocardium. To date, there is no treatment to
reverse the process already present at diagnosis; however, new pharmacologic therapies
have shown promise in slowing down disease progression.
1
,- Nitsche C
- Scully PR
- Patel KP
- Kammerlander AA
- Koschutnik M
- Dona C
- Wollenweber T
- Ahmed N
- Thornton GD
- Kelion AD
- Sabharwal N
- Newton JD
- Ozkor M
- Kennon S
- Mullen M
- Lloyd G
- Fontana M
- Hawkins PN
- Pugliese F
- Menezes LJ
- Moon JC
- Mascherbauer J
- Treibel TA.
Prevalence and outcomes of concomitant aortic stenosis and cardiac amyloidosis.
J Am Coll Cardiol. 2021; 77: 128-139
2
Aortic stenosis (AS) is one of the most common valvopathy, in which treatment is
centered around valvular replacement with either transcatheter aortic valve implantation
(TAVI) or surgical aortic valve replacement (SAVR). Without valvular intervention,
severe symptomatic AS is associated with a poor prognosis and 50% mortality rate within
2 years of diagnosis. Studies have shown the prevalence of transthyretin amyloid deposits,
ranging from 4% to 29%, in patients with severe AS undergoing valvular intervention.
3
With the increasing life expectancy of the general population, many patients with
CA remain suitable candidates for aortic valve replacement. Therefore, we sought to
describe the trends and outcomes of TAVI and SAVR in patients who were diagnosed with
concomitant CA and severe AS.To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to American Journal of CardiologyAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Prevalence and outcomes of concomitant aortic stenosis and cardiac amyloidosis.J Am Coll Cardiol. 2021; 77: 128-139
- Aging, aortic stenosis, and transthyretin cardiac amyloidosis: a perfect cardiac storm?.JACC Cardiooncol. 2021; 3: 577-579
- Pathology of transcatheter valve therapy.JACC Cardiovasc Interv. 2012; 5: 582-590
- Aortic valve replacement in patients with amyloidosis.J Thorac Cardiovasc Surg. 2018; 156: 98-103
- Protection against cerebral embolism during transcatheter aortic valve replacement.J Am Coll Cardiol. 2017; 69: 367-377
- Stroke after surgical versus transfemoral transcatheter aortic valve replacement in the PARTNER trial.J Am Coll Cardiol. 2018; 72: 2415-2426
Article Info
Publication History
Published online: July 22, 2022
Received in revised form:
June 15,
2022
Received:
May 19,
2022
Publication stage
In Press Journal Pre-ProofIdentification
Copyright
© 2022 Elsevier Inc. All rights reserved.
